Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | GSR | P00390 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ditiomustine SCHEMBL607073 | 0.92 | ALDH1A1 (0.74) | BLMPMP22ALDH1A1MEN1ABCB11 | |
| SCHEMBL9856739 | 0.87 | BLM (0.76) | BLMPMP22ALDH1A1MEN1ABCB11 | |
| SCHEMBL9856556 | 0.80 | ALDH1A1 (0.70) | BLMPMP22ALDH1A1MEN1ABCB11 | |
| Carmustine SCHEMBL4503 | 0.79 | ALDH1A1 (1.00) | BLMPMP22ALDH1A1MEN1ABCB11 | |
| Carmustine SCHEMBL2047318 | 0.79 | ALDH1A1 (1.00) | BLMPMP22ALDH1A1MEN1ABCB11 | |
| SCHEMBL9856783 | 0.79 | ALDH1A1 (0.68) | BLMPMP22ALDH1A1MEN1ABCB11 | |
| Carmustine SCHEMBL5783727 | 0.78 | ALDH1A1 (0.89) | BLMPMP22ALDH1A1MEN1ABCB11 | |
| Elmustine SCHEMBL93476 | 0.77 | ALDH1A1 (0.82) | BLMPMP22ALDH1A1MEN1ABCB11 | |
| SCHEMBL11053528 | 0.75 | ALDH1A1 (0.72) | BLMPMP22ALDH1A1MEN1ABCB11 | |
| SCHEMBL10005923 | 0.74 | ALDH1A1 (0.77) | BLMPMP22ALDH1A1MEN1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3779446-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASE USING SALMONELLA T3SS EFFECTOR PROTEIN (SIPA) | University of Massachusetts (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20210023169-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASE USING SALMONELLA T3SS EFFECTOR PROTEIN (SipA) | UNIVERSITY OF MASSACHUSETTS | 2021-01-28 | — | — | US | disclosed |
| US-10835575-B2 | Compositions and methods for treating disease using Salmonella T3SS effector protein (SipA) | UNIVERSITY OF MASSACHUSETTS (US) | 2020-11-17 | — | — | US | disclosed |
| EP-3084445-B1 | COMPOSITIONS AND METHODS FOR TREATING DISEASE USING SALMONELLA T3SS EFFECTOR PROTEIN (SIPA) | UNIV MASSACHUSETTS (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20190240286-A1 | Compositions and Methods for Treating Disease Using Salmonella T3SS Effector Protein (SipA) | UNIVERSITY OF MASSACHUSETTS | 2019-08-08 | — | — | US | disclosed |
| US-10201589-B2 | Compositions and methods for treating disease using Salmonella T3SS effector protein (SipA) | UNIVERSITY OF MASSACHUSETTS (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170035837-A1 | Compositions and Methods for Treating Disease Using Salmonella T3SS Effector Protein (SipA) | UNIVERSITY OF MASSACHUSETTS (US) | 2017-02-09 | — | — | US | disclosed |
| EP-3084445-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASE USING SALMONELLA T3SS EFFECTOR PROTEIN (SIPA) | University of Massachusetts (US) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015089268-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASE USING SALMONELLA T3SS EFFECTOR PROTEIN (SIPA) | UNIVERSITY OF MASSACHUSETTS (US) | 2015-06-18 | — | — | WO | disclosed |
| EP-2181704-B1 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INT AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| US-20040191843-A1 | Cell-killing molecules and methods of use thereof | PALO ALTO INSTITUTE OF MOLECULAR MEDICINE | 2004-09-30 | — | — | US | disclosed |
| WO-2004070012-A2 | CELL-KILLING MOLECULES AND METHODS OF USE THEREOF | PALO ALTO INSTITUTE OF MOLECULAR MEDICINE (US) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004060346-A2 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | ANGIOTECH INTERNATIONAL AG (CH) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060405-A2 | TISSUE REACTIVE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | ANGIOTECH INTERNATIONAL AG (CH) | 2004-07-22 | — | — | WO | disclosed |
| US-20030216758-A1 | Coated surgical patches | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2003-11-20 | — | — | US | disclosed |
| US-20030144570-A1 | Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2003-07-31 | — | — | US | disclosed |
| WO-2003059408-A2 | SURGICAL PATCHES WITH A BIOLOGICAL ACTIVE AGENT | ANGIOTECH INTERNATIONAL AG (CH) | 2003-07-24 | — | — | WO | disclosed |
| EP-1235598-A2 | COMPOSITIONS OF A COMBINATION OF RADIOACTIVE THERAPY AND CELL-CYCLE INHIBITORS | Angiotech Pharmaceuticals, Inc. (CA) | 2002-09-04 | — | — | EP | disclosed |
| US-20020055666-A1 | Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors | ANGIOTECH INTERNATIONAL AG (CH) | 2002-05-09 | — | — | US | disclosed |
| WO-2001036007-A2 | COMPOSITIONS OF A COMBINATION OF RADIOACTIVE THERAPY AND CELL-CYCLE INHIBITORS | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210023169-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASE USING SALMONELLA T3SS EFFECTOR PROTEIN (SipA) | TP53, CIP2A, ABCC1 | BLM 1073/4885PMP22 2519/4885ALDH1A1 3162/4885 |
| US-10835575-B2 | Compositions and methods for treating disease using Salmonella T3SS effector protein (SipA) | TP53, CIP2A, ABCC1 | BLM 1073/4885PMP22 2519/4885ALDH1A1 3162/4885 |
| US-20190240286-A1 | Compositions and Methods for Treating Disease Using Salmonella T3SS Effector Protein (SipA) | TP53, CIP2A, ABCC1 | BLM 1073/4885PMP22 2519/4885ALDH1A1 3162/4885 |
| US-20170035837-A1 | Compositions and Methods for Treating Disease Using Salmonella T3SS Effector Protein (SipA) | TP53, CIP2A, ABCC1 | BLM 1073/4885PMP22 2519/4885ALDH1A1 3162/4885 |
| US-10201589-B2 | Compositions and methods for treating disease using Salmonella T3SS effector protein (SipA) | TP53, CIP2A, ABCC1 | BLM 1073/4885PMP22 2519/4885ALDH1A1 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.